Head to Head Analysis: Enzo Biochem (NYSE:ENZ) and Grail (NASDAQ:GRAL)

Enzo Biochem (NYSE:ENZ) and Grail (NASDAQ:GRAL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations.

Valuation and Earnings

This table compares Enzo Biochem and Grail”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enzo Biochem	$31.91 million	1.11	-$26.08 million	N/A	N/A
Grail	$117.67 million	5.06	N/A	N/A	N/A

Grail has higher revenue and earnings than Enzo Biochem.

Profitability

This table compares Enzo Biochem and Grail’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enzo Biochem	-81.73%	-11.84%	-8.31%
Grail	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations for Enzo Biochem and Grail, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enzo Biochem	0	0	0	0	0.00
Grail	0	3	0	0	2.00

Grail has a consensus price target of $16.00, suggesting a potential downside of 9.76%. Given Grail’s stronger consensus rating and higher probable upside, analysts plainly believe Grail is more favorable than Enzo Biochem.

Institutional & Insider Ownership

36.9% of Enzo Biochem shares are held by institutional investors. 11.4% of Enzo Biochem shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Grail beats Enzo Biochem on 7 of the 9 factors compared between the two stocks.

About Enzo Biochem

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

About Grail

GRAIL, Inc. is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.